(TMV) TeamViewer - Ratings and Ratios
Remote Access, Enterprise Connectivity, Frontline Workflow, Device Support, AR
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 43.0% |
| Value at Risk 5%th | 55.5% |
| Relative Tail Risk | -21.56% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.99 |
| Alpha | -43.62 |
| CAGR/Max DD | -0.35 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.416 |
| Beta | 0.192 |
| Beta Downside | 0.011 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.99% |
| Mean DD | 27.63% |
| Median DD | 28.32% |
Description: TMV TeamViewer November 13, 2025
TeamViewer SE (XETRA: TMV) develops and sells remote-connectivity software, including the flagship TeamViewer Remote for consumer and SMB users, the enterprise-grade Tensor platform, Frontline for digital workflow assistance, and Dex for AI-driven diagnostics. The suite is complemented by AR/MR tools that target logistics, manufacturing, and after-sales processes. Founded in 2005 and based in Göppingen, Germany, the firm operates globally through a subscription-based SaaS model.
Key recent metrics (FY 2023): revenue of €735 million (+13 % YoY), annual recurring revenue (ARR) growth of ~15 % driven largely by enterprise contracts, and a net-loss of €45 million reflecting continued investment in product expansion and R&D. The remote-work trend and increasing digitalization of field services act as sector tailwinds, while pricing pressure from competitors such as LogMeIn and emerging AI-enabled platforms represents a material risk. The company’s gross margin remains robust at ~80 %, but operating leverage is constrained by high sales-and-marketing spend (≈30 % of revenue).
For a deeper quantitative assessment, you may want to explore ValueRay’s detailed financial model and scenario analysis for TMV.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (115.6m TTM) > 0 and > 6% of Revenue (6% = 43.9m TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA -9.53pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -105.3% (prev -67.85%; Δ -37.40pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.20 (>3.0%) and CFO 336.9m > Net Income 115.6m (YES >=105%, WARN >=100%) |
| Net Debt (389.4m) to EBITDA (191.2m) ratio: 2.04 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (157.0m) change vs 12m ago -0.92% (target <= -2.0% for YES) |
| Gross Margin 87.38% (prev 87.07%; Δ 0.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 54.34% (prev 64.32%; Δ -9.98pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.70 (EBITDA TTM 191.2m / Interest Expense TTM 23.2m) >= 6 (WARN >= 3) |
Altman Z'' -1.85
| (A) -0.46 = (Total Current Assets 107.2m - Total Current Liabilities 876.4m) / Total Assets 1.67b |
| (B) 0.07 = Retained Earnings (Balance) 108.8m / Total Assets 1.67b |
| (C) 0.12 = EBIT TTM 155.3m / Avg Total Assets 1.34b |
| (D) 0.18 = Book Value of Equity 278.8m / Total Liabilities 1.54b |
| Total Rating: -1.85 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 85.88
| 1. Piotroski 6.0pt |
| 2. FCF Yield 14.36% |
| 3. FCF Margin 25.67% |
| 4. Debt/Equity 3.39 |
| 5. Debt/Ebitda 2.04 |
| 6. ROIC - WACC (= 21.18)% |
| 7. RoE 108.1% |
| 8. Rev. Trend 99.11% |
| 9. EPS Trend 48.61% |
What is the price of TMV shares?
Over the past week, the price has changed by +2.31%, over one month by +2.67%, over three months by -32.18% and over the past year by -39.12%.
Is TMV a buy, sell or hold?
What are the forecasts/targets for the TMV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10.6 | 82.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 4.7 | -19.4% |
TMV Fundamental Data Overview December 21, 2025
Market Cap EUR = 890.0m (890.0m EUR * 1.0 EUR.EUR)
P/E Trailing = 7.7671
P/E Forward = 4.6019
P/S = 1.2178
P/B = 6.6355
P/EG = 0.2739
Beta = 1.05
Revenue TTM = 730.8m EUR
EBIT TTM = 155.3m EUR
EBITDA TTM = 191.2m EUR
Long Term Debt = 537.4m EUR (from longTermDebt, last quarter)
Short Term Debt = 115.5m EUR (from shortTermDebt, last fiscal year)
Debt = 444.6m EUR (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 389.4m EUR (from netDebt column, last fiscal year)
Enterprise Value = 1.31b EUR (890.0m + Debt 444.6m - CCE 27.9m)
Interest Coverage Ratio = 6.70 (Ebit TTM 155.3m / Interest Expense TTM 23.2m)
FCF Yield = 14.36% (FCF TTM 187.6m / Enterprise Value 1.31b)
FCF Margin = 25.67% (FCF TTM 187.6m / Revenue TTM 730.8m)
Net Margin = 15.82% (Net Income TTM 115.6m / Revenue TTM 730.8m)
Gross Margin = 87.38% ((Revenue TTM 730.8m - Cost of Revenue TTM 92.2m) / Revenue TTM)
Gross Margin QoQ = 86.75% (prev 86.70%)
Tobins Q-Ratio = 0.78 (Enterprise Value 1.31b / Total Assets 1.67b)
Interest Expense / Debt = 2.35% (Interest Expense 10.4m / Debt 444.6m)
Taxrate = 26.94% (10.6m / 39.2m)
NOPAT = 113.5m (EBIT 155.3m * (1 - 26.94%))
Current Ratio = 0.12 (Total Current Assets 107.2m / Total Current Liabilities 876.4m)
Debt / Equity = 3.39 (Debt 444.6m / totalStockholderEquity, last quarter 131.2m)
Debt / EBITDA = 2.04 (Net Debt 389.4m / EBITDA 191.2m)
Debt / FCF = 2.08 (Net Debt 389.4m / FCF TTM 187.6m)
Total Stockholder Equity = 106.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.93% (Net Income 115.6m / Total Assets 1.67b)
RoE = 108.1% (Net Income TTM 115.6m / Total Stockholder Equity 106.9m)
RoCE = 24.11% (EBIT 155.3m / Capital Employed (Equity 106.9m + L.T.Debt 537.4m))
RoIC = 26.24% (NOPAT 113.5m / Invested Capital 432.6m)
WACC = 5.05% (E(890.0m)/V(1.33b) * Re(6.72%) + D(444.6m)/V(1.33b) * Rd(2.35%) * (1-Tc(0.27)))
Discount Rate = 6.72% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -3.66%
[DCF Debug] Terminal Value 79.38% ; FCFE base≈197.6m ; Y1≈213.4m ; Y5≈264.2m
Fair Price DCF = 29.37 (DCF Value 4.61b / Shares Outstanding 157.0m; 5y FCF grow 9.07% → 3.0% )
EPS Correlation: 48.61 | EPS CAGR: 6.93% | SUE: -1.71 | # QB: 0
Revenue Correlation: 99.11 | Revenue CAGR: 10.06% | SUE: -0.88 | # QB: 0
EPS next Year (2026-12-31): EPS=1.09 | Chg30d=-0.019 | Revisions Net=-2 | Growth EPS=+1.1% | Growth Revenue=+3.5%